Frank Bretz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3357484/publications.pdf

Version: 2024-02-01

76196 17055 16,575 166 40 122 citations h-index g-index papers 180 180 180 23591 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Simultaneous Inference in General Parametric Models. Biometrical Journal, 2008, 50, 346-363.	0.6	10,085
2	Computation of Multivariate Normal and t Probabilities. Lecture Notes in Statistics, 2009, , .	0.1	505
3	Multiple Comparisons Using R. , 0, , .		389
4	A graphical approach to sequentially rejective multiple test procedures. Statistics in Medicine, 2009, 28, 586-604.	0.8	311
5	Combining Multiple Comparisons and Modeling Techniques in Dose-Response Studies. Biometrics, 2005, 61, 738-748.	0.8	305
6	Comparison of Methods for the Computation of Multivariate <i>t</i> Probabilities. Journal of Computational and Graphical Statistics, 2002, 11, 950-971.	0.9	266
7	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts. Biometrical Journal, 2006, 48, 623-634.	0.6	235
8	Adaptive designs for confirmatory clinical trials. Statistics in Medicine, 2009, 28, 1181-1217.	0.8	208
9	Innovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials. Journal of Biopharmaceutical Statistics, 2007, 17, 965-995.	0.4	174
10	Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Statistics in Medicine, 2009, 28, 1445-1463.	0.8	168
11	Twentyâ€five years of confirmatory adaptive designs: opportunities and pitfalls. Statistics in Medicine, 2016, 35, 325-347.	0.8	166
12	Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests. Biometrical Journal, 2011, 53, 894-913.	0.6	123
13	Numerical computation of multivariate <i>t</i> -probabilities with application to power calculation of multiple contrasts. Journal of Statistical Computation and Simulation, 1999, 63, 103-117.	0.7	121
14	Modelâ€based dose finding under model uncertainty using general parametric models. Statistics in Medicine, 2014, 33, 1646-1661.	0.8	121
15	Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroniâ€based closed tests. Statistics in Medicine, 2008, 27, 4914-4927.	0.8	104
16	Assessment of Optimal Selected Prognostic Factors. Biometrical Journal, 2004, 46, 364-374.	0.6	101
17	Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations. Biometrical Journal, 2006, 48, 635-643.	0.6	101
18	Optimal Designs for Dose-Finding Studies. Journal of the American Statistical Association, 2008, 103, 1225-1237.	1.8	96

#	Article	lF	CITATIONS
19	Estimands in clinical trials – broadening the perspective. Statistics in Medicine, 2017, 36, 5-19.	0.8	96
20	Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics, 2007, 6, 161-170.	0.7	90
21	Adaptive Dunnett tests for treatment selection. Statistics in Medicine, 2008, 27, 1612-1625.	0.8	89
22	On the Numerical Availability of Multiple Comparison Procedures. Biometrical Journal, 2001, 43, 645-656.	0.6	84
23	Multiple Testing in Group Sequential Trials Using Graphical Approaches. Statistics in Biopharmaceutical Research, 2013, 5, 311-320.	0.6	81
24	Dose Finding – A Challenge in Statistics. Biometrical Journal, 2008, 50, 480-504.	0.6	80
25	Design and Analysis of Dose-Finding Studies Combining Multiple Comparisons and Modeling Procedures. Journal of Biopharmaceutical Statistics, 2006, 16, 639-656.	0.4	74
26	Hierarchical testing of multiple endpoints in groupâ€sequential trials. Statistics in Medicine, 2010, 29, 219-228.	0.8	70
27	Powerful short-cuts for multiple testing procedures with special reference to gatekeeping strategies. Statistics in Medicine, 2007, 26, 4063-4073.	0.8	69
28	Beyond Randomized Clinical Trials: Use of External Controls. Clinical Pharmacology and Therapeutics, 2020, 107, 806-816.	2.3	65
29	Advanced multiplicity adjustment methods in clinical trials. Statistics in Medicine, 2014, 33, 693-713.	0.8	61
30	"Thresholdâ€crossing― A Useful Way to Establish the Counterfactual in Clinical Trials?. Clinical Pharmacology and Therapeutics, 2016, 100, 699-712.	2.3	61
31	Practical considerations for optimal designs in clinical dose finding studies. Statistics in Medicine, 2010, 29, 731-742.	0.8	60
32	A Simulation Study to Compare New Adaptive Dose–Ranging Designs. Statistics in Biopharmaceutical Research, 2010, 2, 487-512.	0.6	58
33	MCPMod : An <i>R</i> Package for the Design and Analysis of Dose-Finding Studies. Journal of Statistical Software, 2009, 29, .	1.8	55
34	An extension of the Williams trend test to general unbalanced linear models. Computational Statistics and Data Analysis, 2006, 50, 1735-1748.	0.7	53
35	Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014). CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 418-429.	1.3	52
36	Adaptive Dose-Response Studies. Drug Information Journal, 2006, 40, 451-461.	0.5	50

#	Article	IF	CITATIONS
37	Nonparametric All-Pairs Multiple Comparisons. Biometrical Journal, 2001, 43, 571-580.	0.6	47
38	Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures. Statistics in Medicine, 2011, 30, 1489-1501.	0.8	45
39	Estimands and Their Role in Clinical Trials. Statistics in Biopharmaceutical Research, 2017, 9, 268-271.	0.6	45
40	Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine, 2007, 26, 4925-4938.	0.8	44
41	Optimal designs for the emax, log-linear and exponential models. Biometrika, 2010, 97, 513-518.	1.3	43
42	Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials. Statistics in Medicine, 2017, 36, 1334-1360.	0.8	42
43	Alterations of pre-mRNA splicing in human inflammatory bowel disease. European Journal of Cell Biology, 2011, 90, 603-611.	1.6	41
44	Statistical Analysis of Monotone or Non-monotone Dose–Response Data from <i>In Vitro</i> Toxicological Assays. ATLA Alternatives To Laboratory Animals, 2003, 31, 81-96.	0.7	40
45	Assessing Nonsuperiority, Noninferiority, or Equivalence When Comparing Two Regression Models Over a Restricted Covariate Region. Biometrics, 2009, 65, 1279-1287.	0.8	40
46	Adaptive and Model-Based Dose-Ranging Trials: Quantitative Evaluation and Recommendations. White Paper of the PhRMA Working Group on Adaptive Dose-Ranging Studies. Statistics in Biopharmaceutical Research, 2010, 2, 435-454.	0.6	40
47	Machine learning for clinical trials in the era of COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 506-517.	0.6	40
48	Model selection versus model averaging in dose finding studies. Statistics in Medicine, 2016, 35, 4021-4040.	0.8	37
49	Analysis of Dose–Response Studies—Modeling Approaches. , 2006, , 146-171.		37
50	Simultaneous confidence sets and confidence intervals for multiple ratios. Journal of Statistical Planning and Inference, 2006, 136, 2640-2658.	0.4	36
51	Response-adaptive dose-finding under model uncertainty. Annals of Applied Statistics, 2011, 5, .	0.5	34
52	Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics, 2011, 10, 96-104.	0.7	33
53	Estimands: discussion points from the PSI estimands and sensitivity expert group. Pharmaceutical Statistics, 2017, 16, 6-11.	0.7	32
54	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. Statistics in Biopharmaceutical Research, 2020, 12, 461-477.	0.6	31

#	Article	IF	CITATIONS
55	Detecting dose-response using contrasts: asymptotic power and sample size determination for binomial data. Statistics in Medicine, 2002, 21, 3325-3335.	0.8	30
56	Identifying effective and/or safe doses by stepwise confidence intervals for ratios. Statistics in Medicine, 2003, 22, 847-858.	0.8	29
57	Efficient design and analysis of two colour factorial microarray experiments. Computational Statistics and Data Analysis, 2006, 50, 499-517.	0.7	29
58	Equivalence of Regression Curves. Journal of the American Statistical Association, 2018, 113, 711-729.	1.8	29
59	Simultaneous Confidence Bands for Nonlinear Regression Models with Application to Population Pharmacokinetic Analyses. Journal of Biopharmaceutical Statistics, 2011, 21, 708-725.	0.4	28
60	TESTING DOSE-RESPONSE RELATIONSHIPS WITH A PRIORI UNKNOWN, POSSIBLY NONMONOTONE SHAPES. Journal of Biopharmaceutical Statistics, 2001, 11, 193-207.	0.4	26
61	Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials. Statistics in Biopharmaceutical Research, 2020, 12, 419-426.	0.6	26
62	Evaluation of Animal Carcinogenicity Studies: Cochran-Armitage Trend Test vs. Multiple Contrast Tests. Biometrical Journal, 2000, 42, 553-567.	0.6	25
63	Shortcuts for Locally Consonant Closed Test Procedures. Journal of the American Statistical Association, 2010, 105, 660-669.	1.8	25
64	Comparison of Methods for the Computation of Multivariate t Probabilities. , 0, .		25
65	Aesthetics and Power Considerations in Multiple Testing – A Contradiction?. Biometrical Journal, 2008, 50, 657-666.	0.6	24
66	Multiplicity issues in microarray experiments. Methods of Information in Medicine, 2005, 44, 431-7.	0.7	23
67	Pooling batches in drug stability study by using constant-width simultaneous confidence bands. Statistics in Medicine, 2007, 26, 2759-2771.	0.8	22
68	Adaptivity in drug discovery and development. Drug Development Research, 2009, 70, 169-190.	1.4	22
69	Multiple and Repeated Testing of Primary, Coprimary, and Secondary Hypotheses. Statistics in Biopharmaceutical Research, 2011, 3, 336-352.	0.6	22
70	Memory and other properties of multiple test procedures generated by entangled graphs. Statistics in Medicine, 2013, 32, 1739-1753.	0.8	20
71	MR imaging of lung parenchyma at 0.2 i; $\frac{1}{2}$ T: evaluation of imaging techniques, comparative study with chest radiography and interobserver analysis. European Radiology, 2004, 14, 703-708.	2.3	19
72	Sample size and proportion of Japanese patients in multiâ€regional trials. Pharmaceutical Statistics, 2010, 9, 207-216.	0.7	18

#	Article	IF	Citations
73	On the efficiency of twoâ€stage responseâ€adaptive designs. Statistics in Medicine, 2013, 32, 1646-1660.	0.8	18
74	Some new methods for the comparison of two linear regression models. Journal of Statistical Planning and Inference, 2007, 137, 57-67.	0.4	17
75	The distribution of extra-pair young within and among broods - a technique to calculate deviations from randomness. Journal of Avian Biology, 2001, 32, 358-363.	0.6	16
76	Power and sample size computations in simultaneous tests for non-inferiority based on relative margins. Statistics in Medicine, 2006, 25, 1131-1147.	0.8	16
77	Normal probability plots with confidence. Biometrical Journal, 2015, 57, 52-63.	0.6	15
78	Multiple Hypotheses Testing Based on Ordered <i>p</i> Valuesâ€"A Historical Survey with Applications to Medical Research. Journal of Biopharmaceutical Statistics, 2011, 21, 595-609.	0.4	14
79	A simple and flexible graphical approach for adaptive group-sequential clinical trials. Journal of Biopharmaceutical Statistics, 2016, 26, 202-216.	0.4	14
80	Commentary on Parker and Weir. Clinical Trials, 2020, 17, 567-569.	0.7	14
81	Reference range: Which statistical intervals to use?. Statistical Methods in Medical Research, 2021, 30, 523-534.	0.7	14
82	The Evaluation of Multiple Clinical Endpoints, with Application to Asthma. Drug Information Journal, 1999, 33, 471-477.	0.5	13
83	Multiplicity and replicability: two sides of the same coin. Pharmaceutical Statistics, 2014, 13, 343-344.	0.7	13
84	A unified framework for weighted parametric multiple test procedures. Biometrical Journal, 2017, 59, 918-931.	0.6	13
85	Assessing the similarity of dose response and target doses in two nonâ€overlapping subgroups. Statistics in Medicine, 2018, 37, 722-738.	0.8	12
86	Robustness considerations in selecting efficient two-color microarray designs. Bioinformatics, 2009, 25, 2355-2361.	1.8	11
87	Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials. JCO Precision Oncology, 2019, 3, 1-10.	1.5	11
88	Title is missing!. Environmental and Ecological Statistics, 2000, 7, 135-154.	1.9	10
89	Multiple Comparison Procedures in Linear Models. , 2008, , 423-431.		10
90	Discussion of "Some Controversial Multiple Testing Problems in Regulatory Applications―by H. M. J. Hung and SJ. Wang. Journal of Biopharmaceutical Statistics, 2009, 19, 25-34.	0.4	10

#	Article	IF	Citations
91	Simultaneous confidence bands for all contrasts of three or more simple linear regression models over an interval. Computational Statistics and Data Analysis, 2010, 54, 1475-1483.	0.7	10
92	Simultaneous inference for several quantiles of a normal population with applications. Biometrical Journal, 2013, 55, 360-369.	0.6	10
93	Confidence Sets for Optimal Factor Levels of a Response Surface. Biometrics, 2016, 72, 1285-1293.	0.8	10
94	Statistical calibration and exact one-sided simultaneous tolerance intervals for polynomial regression. Journal of Statistical Planning and Inference, 2016, 168, 90-96.	0.4	10
95	Adaptive designs: The Swiss Army knife among clinical trial designs?. Clinical Trials, 2017, 14, 417-424.	0.7	10
96	Efficient two-sample designs for microarray experiments with biological replications. In Silico Biology, 2004, 4, 461-70.	0.4	10
97	Estimands and Complex Innovative Designs. Clinical Pharmacology and Therapeutics, 2022, 112, 1183-1190.	2.3	10
98	From Adaptive Design to Modern Protocol Design for Drug Development: Part I. Editorial and Summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum. Drug Information Journal, 2010, 44, 325-331.	0.5	9
99	Dose Response Signal Detection under Model Uncertainty. Biometrics, 2015, 71, 996-1008.	0.8	9
100	Estimands and their Estimators for Clinical Trials Impacted by the COVID-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. Statistics in Biopharmaceutical Research, 2023, 15, 94-111.	0.6	9
101	Trimmed Weighted Simes' Test for Two Oneâ€Sided Hypotheses With Arbitrarily Correlated Test Statistics. Biometrical Journal, 2009, 51, 885-898.	0.6	8
102	Data Monitoring in Adaptive Dose-Ranging Trials. Statistics in Biopharmaceutical Research, 2010, 2, 513-521.	0.6	8
103	Optimal designs for dose finding studies with an active control. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2014, 76, 265-295.	1.1	8
104	Flexible alpha allocation strategies for confirmatory adaptive enrichment clinical trials with a prespecified subgroup. Statistics in Medicine, 2018, 37, 3387-3402.	0.8	8
105	Replicability, Reproducibility, and Multiplicity in Drug Development. Chance, 2019, 32, 4-11.	0.1	8
106	Adaptive designs based on the truncated product method. BMC Medical Research Methodology, 2005, 5, 30.	1.4	7
107	Exact Simultaneous Confidence Bands for Quadratic and Cubic Polynomial Regression with Applications in Dose Response Study. Australian and New Zealand Journal of Statistics, 2013, 55, 421-434.	0.4	7
108	Optimal designs for active controlled dose-finding trials with efficacy-toxicity outcomes. Biometrika, 2017, 104, 1003-1010.	1.3	7

#	Article	IF	Citations
109	Connecting Instrumental Variable methods for causal inference to the Estimand Framework. Statistics in Medicine, 2021, 40, 5605-5627.	0.8	7
110	Preface: Biom. J. 1/2007. Biometrical Journal, 2007, 49, 5-6.	0.6	6
111	A note on testing families of hypotheses using graphical procedures. Statistics in Medicine, 2014, 33, 5340-5346.	0.8	6
112	Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel. Statistics in Medicine, 2015, 34, 3461-3480.	0.8	6
113	Simultaneous confidence bands for a percentile line in linear regression. Computational Statistics and Data Analysis, 2015, 81, 1-9.	0.7	6
114	Equivalence of regression curves sharing common parameters. Biometrics, 2020, 76, 518-529.	0.8	6
115	Editorial: Roles of Hypothesis Testing, p-Values and Decision Making in Biopharmaceutical Research. Statistics in Biopharmaceutical Research, 2021, 13, 1-5.	0.6	6
116	Estimandsâ€"What they are and why they are important for pharmacometricians. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 279-282.	1.3	6
117	Panel forum on multiple comparison procedures: A commentary from a complex trial design and analysis plan. Biometrical Journal, 2013, 55, 275-293.	0.6	5
118	Some Practical Considerations for Phase III Studies With Biomarker Evaluations. Journal of Clinical Oncology, 2014, 32, 854-855.	0.8	5
119	An Exact Confidence Set for a Maximum Point of a Univariate Polynomial Function in a Given Interval. Technometrics, 2015, 57, 559-565.	1.3	5
120	Symmetric graphs for equally weighted tests, with application to the Hochberg procedure. Statistics in Medicine, 2019, 38, 5268-5282.	0.8	5
121	Statistical Challenges in the Conduct and Management of Ongoing Clinical Trials During the COVID-19 Pandemic. Statistics in Biopharmaceutical Research, 2020, 12, 397-398.	0.6	5
122	Approaches for Optimal Dose Selection for Adaptive Design Trials. Statistics in the Health Sciences, 2014, , 125-137.	0.2	5
123	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. Statistics in Medicine, 2021, 40, 6235-6242.	0.8	5
124	Critical point and power calculations for the studentized range test for generally correlated means. Journal of Statistical Computation and Simulation, 2001, 71, 85-97.	0.7	4
125	Comparison of Exact and Resampling Based Multiple Testing Procedures. Communications in Statistics Part B: Simulation and Computation, 2003, 32, 461-473.	0.6	4
126	Simultaneous Tests and Confidence Intervals for the Evaluation of Agricultural Field Trials. Agronomy Journal, 2004, 96, 1323-1330.	0.9	4

#	Article	IF	Citations
127	Multiple confidence intervals for selected parameters adjusted for the false coverage rate in monotone dose–response microarray experiments. Biometrical Journal, 2017, 59, 732-745.	0.6	4
128	Comparison of normal distribution–based and nonparametric decision limits on the GHâ€2000 score for detecting growth hormone misuse (doping) in sport. Biometrical Journal, 2021, 63, 187-200.	0.6	4
129	Missing data imputation in clinical trials using recurrent neural network facilitated by clustering and oversampling. Biometrical Journal, 2022, 64, 863-882.	0.6	4
130	One-sided Simultaneous Confidence Intervals for Effective Dose Steps in Unbalanced Designs. Biometrical Journal, 2000, 42, 995-1006.	0.6	3
131	Dose–Response and Thresholds in Mutagenicity Studies: A Statistical Testing Approach. ATLA Alternatives To Laboratory Animals, 2003, 31, 97-103.	0.7	3
132	Directional Error Rates of Closed Testing Procedures. Statistics in Biopharmaceutical Research, 2013, 5, 345-355.	0.6	3
133	Designing dose-finding studies with an active control for exponential families. Biometrika, 2015, 102, 937-950.	1.3	3
134	Simultaneous Confidence Tubes in Multivariate Linear Regression. Scandinavian Journal of Statistics, 2016, 43, 879-885.	0.9	3
135	Key Aspects of Modern, Quantitative Drug Development. Statistics in Biosciences, 2018, 10, 283-296.	0.6	3
136	Discussion on †Correct and logical causal inference for binary and timeâ€toâ€event outcomes in randomized controlled trials'. Biometrical Journal, 2022, 64, 243-245.	0.6	3
137	Multiplicity in Clinical Trials. , 2010, , 889-896.		3
138	Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation. Statistics in Biopharmaceutical Research, 2023, 15, 554-559.	0.6	3
139	Obtaining Critical Values for Simultaneous Confidence Intervals and Multiple Testing. Biometrical Journal, 2001, 43, 657-663.	0.6	2
140	Bayesian Two-Stage Dose Finding for Cytostatic Agents Via Model Adaptation. Journal of the Royal Statistical Society Series C: Applied Statistics, 2016, 65, 465-482.	0.5	2
141	Comparing a stratified treatment strategy with the standard treatment in randomized clinical trials. Statistics in Medicine, 2016, 35, 5325-5337.	0.8	2
142	The MCP-Mod Methodology: Practical Considerations and the DoseFinding R Package., 2017,, 205-227.		2
143	Confidence Sets for Statistical Classification. Stats, 2019, 2, 332-346.	0.5	2
144	Commentary on "Statistics at FDA: Reflections on the Past Six Years― Statistics in Biopharmaceutical Research, 2019, 11, 20-25.	0.6	2

#	Article	IF	CITATIONS
145	Testing for similarity of binary efficacy–toxicity responses. Biostatistics, 2022, 23, 949-966.	0.9	2
146	Efficient and easy-to-use sample size formulas in ratio-based non-inferiority tests. Journal of Applied Statistics, 2008, 35, 893-900.	0.6	1
147	MCP2009 – 6 th International Conference on Multiple Comparison Procedures. Biometrical Journal, 2010, 52, 705-707.	0.6	1
148	Multiple Contrast Tests for Testing Dose–Response Relationships Under Order-Restricted Alternatives. , 2012, , 233-247.		1
149	Authors' response to comments. Statistics in Medicine, 2016, 35, 364-367.	0.8	1
150	Multiple Test Strategies for Comparing Several Doses with a Control in Confirmatory Trials. , 2017, , 279-290.		1
151	Confidence Sets for Statistical Classification (II): Exact Confidence Sets. Stats, 2019, 2, 439-446.	0.5	1
152	Graphical approaches for the control of generalized error rates. Statistics in Medicine, 2020, 39, 3135-3155.	0.8	1
153	Simultaneous confidence tubes for comparing several multivariate linear regression models. Biometrical Journal, 2021, , .	0.6	1
154	Adaptive Trial Designs. AAPS Advances in the Pharmaceutical Sciences Series, 2011, , 109-130.	0.2	1
155	Adaptive Dose-Ranging Studies. , 2010, , 11-1-11-16.		1
156	Statistical Issues and Challenges in Clinical Trials for COVID-19 Treatments, Vaccines, Medical Devices and Diagnostics. Statistics in Biopharmaceutical Research, 0, , 1-4.	0.6	1
157	Author's reply. Biometrical Journal, 2013, 55, 266-266.	0.6	0
158	Introduction to Multiple Test Problems, with Applications to Adaptive Designs., 2014,, 337-348.		0
159	Seventh international French Society of Statistics meeting on statistical methods in biopharmacy: emerging topics for statistical methodology in clinical drugÂdevelopment. Statistics in Medicine, 2015, 34, 2981-2982.	0.8	0
160	Computation of an exact confidence set for a maximum point of a univariate polynomial function in a given interval. Statistics and Probability Letters, 2017, 122, 157-161.	0.4	0
161	Quantitative approaches underpinning decision making. Biometrical Journal, 2019, 61, 1103-1103.	0.6	0
162	Advanced Topics in Biostatistics: Editorial for the ISCB38 Special Issue. Biometrical Journal, 2019, 61, 243-244.	0.6	0

#	Article	IF	CITATIONS
163	Statistics in Biopharmaceutical Research Best Papers Award. Statistics in Biopharmaceutical Research, 2021, 13, 129-130.	0.6	O
164	Multiplicity in Clinical Trials. , 2012, , 889-896.		0
165	The Need for and the Future of Adaptive Designs in Clinical Development. Statistics in the Health Sciences, 2014, , 3-23.	0.2	O
166	Rationale for the update algorithm of the graphical approach to sequentially rejective multiple test procedures. Pharmaceutical Statistics, 2022, 21, 757-763.	0.7	0